SNY - Sanofi

NYSE - NYSE Delayed price. Currency in USD
39.44
+0.29 (+0.74%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close39.15
Open39.54
Bid0.00 x 1800
Ask0.00 x 800
Day's range39.35 - 39.67
52-week range37.43 - 50.65
Volume4,482,419
Avg. volume1,674,346
Market cap98.555B
Beta0.83
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.86 (4.64%)
Ex-dividend date2018-05-09
1y target est44.00
Trade prices are not sourced from all markets
  • Latecomer Sanofi looks to catch next wave of cancer therapies
    Reuters13 hours ago

    Latecomer Sanofi looks to catch next wave of cancer therapies

    Sanofi missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalize on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumor cells - in the early 2010s.

  • Reuters22 hours ago

    Latecomer Sanofi looks to catch next wave of cancer therapies

    Sanofi missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.

  • What Makes Sanofi (EPA:SAN) An Attractive Investment?
    Simply Wall St.yesterday

    What Makes Sanofi (EPA:SAN) An Attractive Investment?

    Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Sanofi (ENXTPA:SAN) due to its excellent fundamentals in more than oneRead More...

  • Reuters2 days ago

    Sanofi poaches former PSA finance boss Chasseloup de Chatillon

    French drugmaker Sanofi (SASY.PA) announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA (PEUP.PA) who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

  • Sanofi poaches former PSA finance boss Chasseloup de Chatillon
    Reuters2 days ago

    Sanofi poaches former PSA finance boss Chasseloup de Chatillon

    French drugmaker Sanofi (SASY.PA) announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA (PEUP.PA) who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

  • GlobeNewswire2 days ago

    Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

    June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1st 2018.  He will join Sanofi September 1st to ensure a smooth transition with Jérôme Contamine who will retire on September 30th, after more than 9 years of distinguished service at Sanofi. Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group.

  • GlobeNewswire2 days ago

    Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

    NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.

  • EQS Group3 days ago

    EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT INFECTIOUS DISEASES

    DGAP-News: Evotec AG / Key word(s): Miscellaneous18.06.2018 / 07:00 The issuer is solely responsible for the content of this announcement. ACCELERATION OF RESEARCH AND DEVELOPMENT ("R&D") OF NOVEL ANTI-INFECTIVES 100 EMPLOYEES WILL JOIN EVOTEC SANOFI WILL LICENSE MORE THAN 10 INFECTIOUS DISEASE ("ID") R&D ASSETS SANOFI TO PROVIDE SIGNIFICANT SUPPORT TO EVOTEC INCLUDING A ONE-TIME, UPFRONT PAYMENT OF EUR 60 M TO SUPPORT PROGRESSION OF A NEXT GENERATION ANTI-INFECTIVES PORTFOLIO  

  • Sanofi Plots Cancer Comeback With First New Drug in Years
    Bloomberg8 days ago

    Sanofi Plots Cancer Comeback With First New Drug in Years

    Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a contender in the next one. A treatment Sanofi is developing with Regeneron Pharmaceuticals Inc. could go on sale by the end of the year, said Joanne Lager, head of oncology development at the Paris-based company.

  • Sanofi says on track to regain solid position in cancer drugs
    Reuters8 days ago

    Sanofi says on track to regain solid position in cancer drugs

    Sanofi (SASY.PA) believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.

  • GlobeNewswire8 days ago

    Sanofi : Sanofi successfully prices USD 2 billion bond issue

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi successfully prices USD 2 billion bond issue     Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 ...

  • GlobeNewswire10 days ago

    Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

    In doing such a capital increase, Sanofi intends to better associate its employees with the future development and results of the company. On March 6, 2018­ the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is €52.66.

  • The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

  • Top Research Reports for Mastercard, VMware & Sanofi
    Zacks15 days ago

    Top Research Reports for Mastercard, VMware & Sanofi

    Top Research Reports for Mastercard, VMware & Sanofi

  • PR Newswire16 days ago

    New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma

    GUILDFORD, England , June 5, 2018 /PRNewswire/ -- - Patients treated with cemiplimab experienced robust anti-tumour effects - Data also presented today at the 2018 ASCO Annual Meeting, - Cemiplimab applications under review by regulatory authorities in the U.S. and ...

  • GlobeNewswire16 days ago

    Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma   ...

  • A Short Guide to the Novartis-AveXis Deal
    Market Realist17 days ago

    A Short Guide to the Novartis-AveXis Deal

    On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.

  • Analysts’ Recommendations for GlaxoSmithKline in May
    Market Realist17 days ago

    Analysts’ Recommendations for GlaxoSmithKline in May

    GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.

  • Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?
    Zacks17 days ago

    Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?
    Zacks17 days ago

    Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?

    Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • The Wall Street Journal19 days ago

    [$$] Sanofi Says Average Net Price of Its Drugs Fell Last Year

    French drug company Sanofi SA says the average price of its medicines fell 8.4% in the U.S. last year after accounting for rebates, the latest example of pharmaceutical pricing pressures. Several major drug companies have now said the net prices of their medicines—that is, the price of the drugs after discounts and rebates—fell in aggregate in 2017. Johnson & Johnson and Merck & Co. have said the sums paid for their drugs had dropped last year, too.

  • Alphabet's Verily has hired top execs to bring its science research into hospitals and homes
    CNBC19 days ago

    Alphabet's Verily has hired top execs to bring its science research into hospitals and homes

    Alphabet's Verily is adding executives and advisers as it moves to commercialize its research.

  • Analyzing Novartis’s Revenue in Q1
    Market Realist20 days ago

    Analyzing Novartis’s Revenue in Q1

    In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.

  • A Look at GlaxoSmithKline’s Valuation on May 29
    Market Realist20 days ago

    A Look at GlaxoSmithKline’s Valuation on May 29

    GlaxoSmithKline (GSK) is focused on maintaining a sustainable growth model by strategizing its business beyond pharmaceuticals.

  • Top Diabetes Stocks to Buy Today
    Motley Fool21 days ago

    Top Diabetes Stocks to Buy Today

    More people than ever are being diagnosed with diabetes, and big advances in treatment could make these diabetes stocks savvy investments.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes